Sanofi : Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charlès as New Independent Directors
(Thomson Reuters ONE) -
Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and
Bernard Charlès as New Independent Directors
Paris, France - March 2,2017 - At its meeting held on March 2, 2017, the Board
of Directors of Sanofi proposed the appointment of Melanie Lee, PhD and Bernard
Charlès as new independent Directors during the General Shareholders' meeting of
May 10, 2017, as well as the renewal of the term of Fabienne Lecorvaisier.
Melanie Lee, PhD, CBE, is Chief Scientific Officer at BTG plc (since November
2014), a company which operates in interventional medicine in vascular disease,
oncology and pulmonology. Following her academic career she spent 10 years at
Glaxo/GlaxoWellcome (1988-1998). In 1998, Melanie joined Celltech plc as
Executive Director of Research. Celltech plc was subsequently acquired by UCB
where she became Executive Vice President, Research and Development. After
leaving UCB in 2009 she had a successful tenure as CEO at Syntaxin Ltd, a UK
based biotech and following the sale to Ipsen, founded NightstaRx Ltd, a Syncona
backed company in 2014. Melanie received an undergraduate degree in Biology from
the University of York and then a Ph.D. at National Institute for Medical
Research in London. She worked as a molecular genetics postdoc, first at
Imperial College London on yeast and then from 1985 with Sir Paul Nurse, a Nobel
Prize winner, at the Imperial Cancer Research Fund's Lincoln's Inn Laboratories.
Melanie received her CBE for services to medical science in 2009.
Bernard Charlès has served since May 2016 as Vice-Chairman and Chief Executive
Officer of Dassault Systèmes, a world leader in 3D software with over 220,000
customers in 12 industry sectors. He has been CEO of Dassault Systèmes since
September 1995. He joined the company in 1983 and created the New Technology,
Research and Strategy division, before being appointed Director for Strategy,
Research and Development in 1988. Through his contributions to digital mock-up,
product lifecycle management and 3DEXPERIENCE(®), Bernard Charlès helped instill
a culture of ongoing innovation to further consolidate Dassault Systèmes'
scientific capabilities and make science part of the company's identity. Bernard
Charlès is a member of the Academy of Technology (France) and of the National
Academy of Engineering (United States). He is a graduate of the Ecole Normale
Supérieure engineering school in Cachan and has a Ph.D. in mechanical
engineering majoring in automation engineering and information science. He also
holds an Aggregation in mechanical engineering; this is the most senior teaching
qualification achievable in France.
"Melanie Lee is a renowned scientific expert with a deep knowledge of the
pharmaceutical industry and Bernard Charlès has made Dassault Systèmes an
international success. They will bring their strengths to further reinforce the
capabilities of the Board and contribute significantly to Sanofi's strategy,
both in the area of innovation and to the leveraging of opportunities afforded
by digital development," said Serge Weinberg, Chairman of the Board, Sanofi.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
--------------------------------------------------------------------------------
Contacts:
Media Relations Investor Relations
Laurence Bollack George Grofik
+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Press release:
http://hugin.info/152918/R/2084593/785901.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2017 - 18:30 Uhr
Sprache: Deutsch
News-ID 527836
Anzahl Zeichen: 4937
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 333 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi : Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charlès as New Independent Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
